A separate summary of the same Bristol Myers transition frames it as an “evolution” of the company’s R&D structure, with Massacesi gaining additional titles and Plenge departing as the research organization is consolidated. The goal, per company logic described in coverage, is to streamline execution across development and research functions. The change matters for pipeline cadence: consolidated ownership can reduce handoff delays between translational strategy and clinical development. In the near term, industry watchers will look for how BMS reallocates scientific staffing and which therapeutic areas get faster internal decision cycles.